Literature DB >> 29625157

Role of Cyclodextrins in Nanoparticle-Based Drug Delivery Systems.

Haley Shelley1, R Jayachandra Babu2.   

Abstract

Cyclodextrins (CDs) are cyclic oligosaccharides with unique hydrophobic interior surfaces. Three parent CDs, α-CD, β-CD, and γ-CD, are further chemically modified primarily to make them suitable for parenteral administration, and these are used for many pharmaceutical applications. CDs offer distinctive advantages due to their unique ability to form inclusion complexes with a variety of organic and inorganic lipophilic molecules. This attribute is promising for a wide range of fields such as drug delivery, cancer therapy, gene delivery, and biosensing. In recent years, CDs have become more commonly used functional materials in nanoparticle (NP)-based drug delivery. The properties of NPs can be advantageously modified by the inclusion of CDs or their derivatives. CD-conjugated NPs (CD-NPs) have many benefits such as improved drug solubility and serve as drug carriers to specific locations such as cancer cells, which reduces toxicity to normal cells. In addition, CDs can overcome the limitations of NPs such as low encapsulation efficiency and drug loading. This review will discuss the various uses of CDs as it applies to NP-based drug carriers. Specifically, how CDs enhance the characteristics of polymeric, magnetic, lipid, metallic, and mesoporous NPs are discussed.
Copyright © 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biomedical; cyclodextrin; inclusion complexes; nanoparticles; nanotechnology; solubilizing agents

Mesh:

Substances:

Year:  2018        PMID: 29625157     DOI: 10.1016/j.xphs.2018.03.021

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  23 in total

1.  Synthesis and characterization of a new cyclodextrin derivative with improved properties to design oral dosage forms.

Authors:  Agustina García; Josefina Priotti; Ana Victoria Codina; María Delia Vasconi; Ariel D Quiroga; Lucila I Hinrichsen; Dario Leonardi; María Celina Lamas
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

2.  Cyclodextrins in drug delivery: applications in gene and combination therapy.

Authors:  Rebecca M Haley; Riccardo Gottardi; Robert Langer; Michael J Mitchell
Journal:  Drug Deliv Transl Res       Date:  2020-06       Impact factor: 4.617

3.  Use of affinity allows anti-inflammatory and anti-microbial dual release that matches suture wound resolution.

Authors:  Rebecca M Haley; Victoria R Qian; Greg D Learn; Horst A von Recum
Journal:  J Biomed Mater Res A       Date:  2019-03-20       Impact factor: 4.396

4.  Hydroxypropyl Beta Cyclodextrin as a Potential Surface Modifier for Paclitaxel Nanocrystals.

Authors:  Razan Haddad; Nasr Alrabadi; Bashar Altaani; Majed Masadeh; Tonglei Li
Journal:  AAPS PharmSciTech       Date:  2022-08-09       Impact factor: 4.026

5.  Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles.

Authors:  Leon J Khoza; Pradeep Kumar; Admire Dube; Patrick H Demana; Yahya E Choonara
Journal:  Int J Pharm       Date:  2022-06-06       Impact factor: 6.510

Review 6.  Nanotechnology in drug and gene delivery.

Authors:  Selma Hamimed; Marwa Jabberi; Abdelwaheb Chatti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-05-04       Impact factor: 3.195

7.  Citric acid-crosslinked β-cyclodextrin supported zinc peroxide as a biocompatible H2O2 scavenger.

Authors:  Mahtab Pirouzmand; Parya Salahshour Sani; Zarrin Ghasemi; Sajjad Azizi
Journal:  J Biol Inorg Chem       Date:  2020-03-07       Impact factor: 3.358

Review 8.  Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis.

Authors:  Jun Chen; Xixi Zhang; Reid Millican; Jennifer Sherwood; Sean Martin; Hanjoong Jo; Young-Sup Yoon; Brigitta C Brott; Ho-Wook Jun
Journal:  Adv Drug Deliv Rev       Date:  2021-01-09       Impact factor: 15.470

9.  Nanoparticle encapsulation of non-genotoxic p53 activator Inauhzin-C for improved therapeutic efficacy.

Authors:  Nimisha Bhattarai; Jieqiong Wang; Daniel Nguyen; Xiaoxiao Yang; Linh Helmers; Jennifer Paruch; Li Li; Yiwei Zhang; Kun Meng; Alun Wang; Janarthanan Jayawickramarajah; Binghe Wang; Shelya Zeng; Hua Lu
Journal:  Theranostics       Date:  2021-05-12       Impact factor: 11.556

10.  In silico study of medicinal plants with cyclodextrin inclusion complex as the potential inhibitors against SARS-CoV-2 main protease (Mpro) and spike (S) receptor.

Authors:  Doni Dermawan; Bagas Adji Prabowo; Casilda Aulia Rakhmadina
Journal:  Inform Med Unlocked       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.